GlassScriptPhysician profile
Venice L Sanchez
NPI 1609004837
$15,179.71
in general payments reported to CMS, 2019-2025
41 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,294 · 2020: $2,638 · 2021: $2,751 · 2022: $2,087 · 2023: $2,192 · 2024: $1,412 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,409.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,746.48 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Uswm, LLC | $1,717.13 | 2021-2024 | Lucemyra, Zimhi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,624.83 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,461.24 | 2021-2025 | Vraylar |
| Alkermes, INC. | $973.80 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $887.59 | 2019-2022 | |
| Lundbeck LLC | $736.66 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $599.73 | 2019-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $541.25 | 2019-2025 | Fanapt, Hetlioz |
| Mdd US Operations, LLC | $536.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $513.00 | 2019-2025 | Trintellix |
| Allergan, INC. | $512.67 | 2019-2020 | |
| Bausch Health US, LLC | $422.81 | 2019-2024 | Aplenzin |
| Indivior INC. | $384.79 | 2019-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $302.55 | 2019-2024 | Ingrezza |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $296.33 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $295.89 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $213.13 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $170.30 | 2023-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $167.61 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $149.70 | 2020-2022 | |
| Eisai INC. | $110.17 | 2020-2021 | |
| Gilead Sciences, INC. | $103.36 | 2019-2021 | |
| Livanova USA, INC. | $86.28 | 2021-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Merck Sharp & Dohme LLC | $72.93 | 2021-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $70.57 | 2022-2025 | Quviviq, Quviviq |
| Biogen, INC. | $55.96 | 2024-2025 | Zurzuvae |
| Braeburn INC. | $51.63 | 2024-2025 | Brixadi |
| Owp Pharmaceuticals, INC. | $51.55 | 2022-2023 | Lamotrigine, Subvenite |
| Brainsway USA INC | $48.74 | 2019-2022 | |
| Axsome Therapeutics, INC. | $48.39 | 2022-2023 | Auvelity |
| Neos Therapeutics, LP | $36.42 | 2025 | Adzenys Xr-Odt |
| Novo Nordisk INC | $35.54 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.69 | 2019 | |
| Almatica Pharma LLC | $22.35 | 2025 | Loreev Xr |
| Noven Pharmaceuticals, INC. | $22.07 | 2021 | |
| Collegium Pharmaceutical, INC. | $21.14 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.43 | 2020 | |
| Lilly USA, LLC | $19.14 | 2025 | Zepbound |
| Arbor Pharmaceuticals, INC. | $13.52 | 2020 | |
| Alfasigma USA, INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venice Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.